Drugs / Autologous T-regulatory lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03241784 | May 2016 → Jan 2018 | amyotrophic lateral sclerosis | The Methodist Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous T-regulatory lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03241784 ↗ |
| Modality | Cell therapy | “autologous expanded Tregs” NCT03241784 ↗ |
| Route | Intravenous | “intravenous administration of Autologous T-regulatory lymphocytes” NCT03241784 ↗ |